VENN STRATEGIES

Lobbying for UCB, INC. · Biopharmaceutical company dealing in severe diseases in immunology and neurology.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Georgia · House · Senate · $80,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Health Issues

Policies related to biopharmaceutical access and innovation.

Taxation/Internal Revenue Code

International tax, corporate tax rate, and research and development tax issues.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.